Tumor Targeting Chemo, Targeted and Combination Therapies
Chemotherapy and targeted cancer therapy are still considered a first line treatment for many cancers. Unfortunately, a limited number of all cancer patients will benefit from current chemo or targeted cancer therapies, leaving a significant need to develop novel combinatorial therapies and strategies that are tumor targeting.
WHY IS TARGETED CANCER THERAPY IMPORTANT?
Kinase inhibition over the last two decades has been a proven approach to treat patients with cancers which have specific genomic attributes, although patients are often prone to relapse due to their cancer evading treatment through other pathways, and conventional chemotherapy is still the frontline tumor targeting treatment for many cancers. Combinations of multiple drugs are often used, as well as the development of multigenerational drugs for known mutations.
Whilst genomic profiling of patients is now commonplace to identify known mutational drivers, many cancers harbor known oncogenic drivers with no currently available targeted therapies, and even genomically well-characterized tumors often have intrinsic resistance to currently available treatments.
We help drug development organizations determine not just the potential efficacy of novel treatments, but also the underlying mechanisms by which patients' tumors evade treatment so as to discover potential targets for new therapies.
Nilogen’s extensive experience in flow cytometry matched with our optimized panels enable our clients to evaluate the immune landscape, T-cell activation, checkpoint inhibition, ADCCs, myeloid function, phagocytosis and cellular proliferation as well as develop and deploy custom panels.
High Content Confocal Microscopy
Quantify and match the ability of your drug to kill tumor cells with the expression of your target antigen, induce phagocytosis and measure penetration into the tumor microenvironment. Evaluate in conjunction with other proteogenomic assays to link mechanism of action with effect.
Single Cell RNA Sequencing
Enables the quantitative measurements of the molecular activity that underlies the phenotypic diversity of cells within a tumor by sequencing individual cells. Intratumor heterogeneity is common across all tumor types. Accurate characterization of this heterogeneity is essential for determining the mechanisms of cancer pathogenesis and identification of novel targets for immunotherapy and drug development.
TOTALSeq works hand-in-hand with scRNAseq to enable the simultaneous measurement of protein and RNA at the single cell level, providing enhanced cell type identification. Evaluate the impact of drug therapy on up to 130 protein markers in conjunction with the transcriptome of each cell, enabling single cell analysis of individual immune cells in a heterogeneous tumor microenvironment.
Multiplex Immunohistochemistry/Immunofluorescence (mIHC/IF) provides high-throughput multiplex staining and standardized semi-quantitative analysis for highly reproducible, efficient and cost-effective tissue studies. This technique allows the simultaneous detection of multiple markers on a single tissue section, providing a comprehensive view of tissue composition, pre and post treatment.
Kinase Inhibitor Sunitinib
High content confocal imaging enables the quantitation of tumor cell killing in response to ex vivo treatment of tumoroids with Sunitinib, a multi-targeted receptor kinase inhibitor.